Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
PHASE2/PHASE3
400 participants
INTERVENTIONAL
2017-10-08
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF)
NCT00419913
Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF
NCT02099916
Study of Dehydroepiandrosterone Treatment for Poor Responders in In Vitro Fertilization Patients
NCT01535872
Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging
NCT01572025
Does Dehydro Epiandrosterone (DHEA) Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response?
NCT02151006
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Teatment
75mg Dehydroepiandrosterone once daily for minimum ten weeks prior to starting ovarian stimulation
Dehydroepiandrosterone
75mg Dehydroepiandrosterone daily
Comaprator
75mg placebo once daily for minimum ten weeks prior to starting ovarian stimulation
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dehydroepiandrosterone
75mg Dehydroepiandrosterone daily
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Markers for poor ovarian reserve (AMH \<7 pmol/L(\<1.1 ng/ml) and/or AFC\< 7)
* Previous poor response to ovarian stimulation ( ≤3 oocytes with a conventional stimulation protocol)
Exclusion Criteria
* Women with premature ovarian failure / premature menopause (FSH\>40 U/L). Women already taking DHEA.
* Patients with a known allergy to the trial drug or any of the active ingredients in the placebo.
40 Years
42 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Homerton University Hospital NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Homerton Fertility Centre
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017DHEA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.